tbuckley/cabot-search huggingface dataset:
Nontoxic Neonates
Authors: C Washam
Journal: Environmental Health Perspectives (2002)

By-Product May Be a ProblemDue to its well-documented adverse health effects, including throat irritation, cough, and difficulty breathing, nitrogen dioxide (NO 2 ) has long been a prime focus of scientific investigations into indoor air pollution.Nitrous acid (HONO), a by-product of NO 2 , is less well-studied in terms of human health effects of low exposures.But it has chemical characteristics that suggest that it, too, is a potential respiratory irritant and that its presence in the indoor environment is worthy of study.In this month's issue, Kiyoung Lee of the University of California at Davis School of Medicine and his coauthors investigate indoor HONO levels as well as the relationship between indoor concentrations of HONO, NO 2 , and ozone [EHP 110:145-149].Their efforts clearly indicate that HONO is indeed potentially an important factor in indoor air pollution.Gas combustion-simply cooking on a gas range-is known to be a major source of NO 2 in the residential environment.HONO, too, is formed by gas combustion, and is also a by-product of NO 2 reactions with water on indoor surfaces.So its concentration in the indoor environment is affected by several variables, including NO 2 concentrations, ventilation, surface materials, available surface areas, temperature, and humidity.Ozone concentrations indoors appear to be determined largely by outdoor levels.In April and May 1996, the team measured indoor and outdoor HONO, NO 2 , and ozone at 119 Southern California homes.Fifty-seven of the houses were located in a valley area, and 62 were in a mountainous region.The varied nature of the outdoor environment of the houses, as well as certain characteristics of the homes themselves, such as the presence of an air conditioner, gas range, or humidifier, were thought to be significant factors contributing to the levels of the three pollutants and the relationships among them.Analysis of the air samples taken over a six-day period both inside and outside the houses showed that average indoor HONO concentrations were higher than outdoor concentrations, which was unsurprising, given that HONO quickly breaks down outdoors in the presence of sunlight.Indoor NO 2 concentrations were also found to be significantly higher than outdoor concentrations, while indoor ozone concentrations were significantly lower than those outdoors.Indoor HONO concentrations correlated positively with indoor NO 2 concentrations, averaging about 17% of NO 2 levels, but correlated inversely with indoor ozone concentrations.The associations explored by the researchers shed light on some of the factors contributing to what they describe as "substantial" indoor HONO concentrations.Each house's location was found to be associated with certain relationships among the three contaminants.Indoor and outdoor NO 2 levels (and therefore HONO levels) were lower in the mountain sites, which had higher ozone levels, leading the authors to speculate that "it is possible that the association between community and the three
Long-Term Hazards of Polychlorinated Dibenzodioxins and Polychlorinated Dibenzofurans
Authors: J. E. Huff, J. A. Moore, R. Saracci, L. Tomatis
Journal: Environmental Health Perspectives (1980)

During January 10-11, 1978 in Lyon, France, a joint National Institute of Environmental Health Sciences/International Agency for Research on Cancer ad hoc Working Group considered and discussed the feasibility of coordinating epidemiological studies on the long-term hazards associated with the chlorinated dibenzo-p-dioxins and chlorinated dibenzofurans (PCDDs and and PCDFs). Nineteen invited scientists from eight countries presented introductory working papers summarizing the most up-to-date and relevant information available from their individual programs. This report represents the collective views and scientific opinions of the Working Group. The greater part of this document comprises epidemiological studies related to episodes of human exposures. The review begins with a brief section concerning possible routes of human exposure, an overview of the pertinent chemical characteristics, and the salient toxicological properties of the structurally similar PCDDs/PCDFs. The Working Group report ends with recommendations for future activities.
Interactions between Methylsulfonyl PCBs and the Glucocorticoid Receptor
Authors: Maria Johansson, Stefan Nilsson, Bert-Ove Lund
Journal: Environmental Health Perspectives (1998)

Persistent polychlorinated biphenyl (PCB) metabolites were studied with respect to their interaction with the human glucocorticoid receptor (GR). 3-Methylsulphonyl-2,5,6,2',4',5'-hexachlorobiphenyl (3-MeSO2-CB149) was shown to compete with 3H-dexamethasone for binding to the GR, with an IC50 (concentration that inhibits 50%) of approximately 1 microM. Using GRAF cells expressing human GR, glucocorticoid responsive element, and a reporter enzyme, we demonstrated that 3-MeSO2-CB149 functionally acts as an antagonist at the GR (IC50 = 2.7 microM). In accordance with the receptor binding, the antagonism mainly appeared to be of a competitive nature. When studying the competitive binding of 24 methylsulfonyl PCBs (relative to dexamethasone) to GR from mouse liver cytosol, seven compounds had a higher affinity to GR than 3-MeSO2-CB149. Structure-activity relationship studies indicated that the presence of three chlorine atoms in the ortho-position and chlorine and methyl sulfone groups on either end of the molecule (4 and 4'-position) increased the affinity to GR. The relevance of this finding for human health is not known, but PCB methyl sulfones are ubiquitous pollutants present in mother's milk. The results stress the need for studying endocrine disruptors that affect hormonal systems other than sex and thyroidogenic hormones.
INTERLINGUA
Authors: JONAS BRACHFELD
Journal: Annals of Internal Medicine (1966)

Letters and Comments1 October 1966INTERLINGUAJONAS BRACHFELD, M.D.JONAS BRACHFELD, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-65-4-865_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:The noble experiment of publishing summaries in Interlingua in the ANNALShas been going on now for a number of years. I am wondering whether it is not high time to have the results reappraised. I, for one, have always wondered about the audience that presumably would be interested in these summaries. Although I speak and read two Germanic and two Romance languages, in addition to English, I get only a hazy concept of the material when I read one of the Interlingua summaries. I therefore cannot help but wonder what reader has sufficient linguistic background to... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Rancocas Valley Hospital Willingboro, N. J. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1966Volume 65, Issue 4Page: 865-866 Issue Published: 1 October 1966 PDF DownloadLoading ...
CD99 Identifies Disease Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes
Authors: Stephen S. Chung, Wendy W Pang, Gino K. In, Max Jan, Virginia M. Klimek, Ari Melnick, Irving L. Weissman, Ravi Majeti, Christopher Y. Park
Journal: Blood (2012)
Blood pressure after stroke
Authors: J. D. Wallace
Journal: JAMA (1981)

In 334 consecutive admissions for acute stroke, the blood pressure was elevated in 84% on the day of admission. The blood pressure decreased spontaneously an average of 20 mm Hg systolic and 10 mm Hg diastolic in the ten days following the acute event without specific antihypertensive therapy and was elevated in only one third of the cases on the tenth hospital day. The early elevation in blood pressure is likely a physiological response to brain ischemia, and blood pressure falls as recovery of brain function occurs. (<i>JAMA</i>1981;246:2177-2180)
ANGIOMA SERPIGINOSUM
Authors: HAMILTON MONTGOMERY, RICHARD J. BAILEY
Journal: British Journal of Dermatology (1935)

British Journal of DermatologyVolume 47, Issue 11 p. 456-463 ANGIOMA SERPIGINOSUM HAMILTON MONTGOMERY M.D., HAMILTON MONTGOMERY M.D. Section of Dermatology and Syphilology, The Mayo Clinic, andSearch for more papers by this authorRICHARD J. BAILEY M.D., RICHARD J. BAILEY M.D. Fellow in Dermatology and Syphilology, The Mayo Foundation, Rochester, Minnesota.Search for more papers by this author HAMILTON MONTGOMERY M.D., HAMILTON MONTGOMERY M.D. Section of Dermatology and Syphilology, The Mayo Clinic, andSearch for more papers by this authorRICHARD J. BAILEY M.D., RICHARD J. BAILEY M.D. Fellow in Dermatology and Syphilology, The Mayo Foundation, Rochester, Minnesota.Search for more papers by this author First published: November 1935 https://doi.org/10.1111/j.1365-2133.1935.tb10221.xCitations: 6Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume47, Issue11November 1935Pages 456-463 RelatedInformation
Viral hepatitis, type B (MS-2 strain). Studies on active immunization
Authors: S. Krugman
Journal: JAMA (1971)

Viral hepatitis, type B (MS-2) was prevented by active and passive immunization. Active immunization was induced by inoculation of a boiled, inactivated preparation of a 1:10 dilution of MS-2 serum in distilled water; two inoculations at four-month intervals were more effective than one. However, one inoculation gave enough protection to prevent some cases and modify others.
New prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma
Authors: Anne Olbrich, Olga Groß, Karen Rother, Tim-Ole Petersen, Bettina Maiwald, Timm Denecke, Thomas Kahn, Florian Lordick, Dirk Forstmeyer, Thomas Lincke, Sandra Purz, Osama Sabri, Robert Sucher, Daniel Seehofer, Thomas Berg, Florian van Bömmel
Journal: Journal of Hepatology (2020)
PUL01.02 AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC
Authors: B. Besse, E. Felip, E.S. Kim, C. Clifford, M. Louie-Gao, A. Yagui-Beltran, S. Popat
Journal: Journal of Thoracic Oncology (2021)
Socioeconomic deprivation and rheumatoid disease: What lessons for the health service?
Authors: E. S. Group
Journal: Annals of the Rheumatic Diseases (2000)

To assess how socioeconomic deprivation influences the presentation, treatment, and outcome of patients with rheumatoid arthritis (RA).Three year follow up of 869 consecutive patients with RA from nine hospital rheumatology clinics, with patients categorised by the Carstairs deprivation score of their enumeration district of residence. Outcomes included Health Assessment Questionnaire (HAQ), joint and pain scores, grip strength, functional grade, radiological evidence of bony erosions, and medical/surgical interventions.Patients from more deprived enumeration districts presented with more severe disease as judged by the HAQ score and joint scores. An increase from the 5th to the 95th centile of the Carstairs distribution was associated with an odds ratio of 1.87 (95% confidence interval (95% CI) 1.31 to 2.66) for an above-median HAQ score and 1.77 (95% CI 1.23 to 2.54) for an above-median joint score. Statistically non-significant deprivation trends were seen with erythrocyte sedimentation rate, pain score, and grip strength. By three years, despite no important differences in clinical management, socioeconomic differentials had worsened or remained unchanged such that clear deprivation trends were then seen in HAQ (p=0.002) and joint scores (p=0.001), in grip strength (p=0. 008), and in functional grade (p=0.003). The association between deprivation and HAQ at three years was present after adjustment for age, sex, treatment centre, and HAQ at presentation (adjusted odds ratio 1.74, 95% CI 1.1 to 2.74).Socioeconomic deprivation was associated with a worse clinical course of rheumatoid disease, and this effect was already apparent at presentation, but not with systematic differentials in its treatment. This suggests that individual susceptibility and lifestyle factors contribute to socioeconomic differentials in outcome, an observation that has implications for clinical management.
Palliative Options of Last Resort
Authors: Timothy E. Quill
Journal: JAMA (1997)

Palliative care is generally agreed to be the standard of care for the dying, but there remain some patients for whom intolerable suffering persists. In the face of ethical and legal controversy about the acceptability of physicianassisted suicide and voluntary active euthanasia, voluntarily stopping eating and drinking and terminal sedation have been proposed as ethically superior responses of last resort that do not require changes in professional standards or the law. The clinical and ethical differences and similarities between these 4 practices are critically compared in light of the doctrine of double effect, the active/ passive distinction, patient voluntariness, proportionality between risks and benefits, and the physician's potential conflict of duties. Terminal sedation and voluntarily stopping eating and drinking would allow clinicians to remain responsive to a wide range of patient suffering, but they are ethically and clinically more complex and closer to physician-assisted suicide and voluntary active euthanasia than is ordinarily acknowledged. Safeguards are presented for any medical action that may hasten death, including determining that palliative care is ineffective, obtaining informed consent, ensuring diagnostic and prognostic clarity, obtaining an independent second opinion, and implementing reporting and monitoring processes. Explicit public policy about which of these practices are permissible would reassure the many patients who fear a bad death in their future and allow for a predictable response for the few whose suffering becomes intolerable in spite of optimal palliative care.
RENAL HEMATURIA.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survival in Systemic Sclerosis–related Pulmonary Arterial Hypertension in the Modern Treatment Era
Authors: Robin Condliffe, David G. Kiely, Andrew J. Peacock, Paul A. Corris, J. Simon R. Gibbs, Joanna Pepke-Zaba, J. Gerry Coghlan
Journal: American Journal of Respiratory and Critical Care Medicine (2009)
Heart Transplantation
Authors: Roy E. Brackin
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hormone Receptors
Authors: John D. Baxter, John W. Funder
Journal: New England Journal of Medicine (1979)

This article reviews the literature on hormone receptors and presents information on the following broad topics: 1) steroid hormone receptors (vs. cytoplasmic); 2) thyroid hormone receptors; 3) catecholamine and peptide hormone receptors; 4) internalization of polypeptide and catecholamine hormone-receptor complexes; 5) affinity (as the basis for discrimination of hormonal signals); 6) binding curves and Scatchard plots; 7) nonspecific and nonreceptor binding; 8) curvilinear Scatchard plots, indicating multiple sites and negative cooperativity; 9) definition of class of hormone action and hormonal occupancy of several classes of receptors; 10) receptor-response relation (close coupling and spare receptors); 11) regulation of receptors (a mechanism important for control of cellular sensitivity to hormones); 12) hormone antagonists and partial agonists and antagonists; 13) receptors and the clinical evaluation of hormone and drug levels; and 14) receptor-related diseases. Throughout the literature, identification of hormone-binding sites as receptors has relied mainly on correlations between hormone binding and biologic effects, on genetic and other studies where loss of (or changes in) receptors are associated with altered hormone responsiveness, and on the finding that receptor binding by anti-receptor antibodies or antagonists attentuates or abolishes the hormone responses.
Management of antiangiogenics’ renovascular safety in ovarian cancer subgroup and intermediate results of the MARS study.
Authors: Vincent Launay-Vacher, Nicolas Janus, Joseph Gligorov, Frédéric Selle, Francois Goldwasser, Olivier Mir, Jean-Philippe Spano, Jean Christophe Thery, Philippe Beuzeboc, Catherine Daniel, Jean-Baptiste Rey, Christelle Jouannaud, Jean F. Morere, Stephane Oudard, Michel Azizi, Richard Dorent, Gilbert Deray, Isabelle Ray-Coquard
Journal: Journal of Clinical Oncology (2012)

5067 Background: Anti-VEGF drugs (AVD) are widely used in cancer patients (pts). Hypertension (HTN) and proteinuria (Pu) are class-side-effects of AVD, related to the inhibition of the VEGF pathway. The MARS study has been conducted to assess the renovascular tolerance of these drugs in the clinical setting. Methods: Hypertension (HTN) and proteinuria (Pu) are class-side-effects of anti-VEGF drugs (AVD), related to the inhibition of the VEGF pathway. The MARS study has been conducted to assess the renovascular tolerance of these drugs in the clinical setting. Results: Among 77 OC pts been included, 38 completed the study to date (1-year follow-up (f/u)). Median age at inclusion (introduction of the AVD) was 62 years. Diabetes and HTN prevalences were 5.2% and 7.9%, respectively. Baseline renal assessment retrieved: Pu 13.2%, Hu 7.9%, mean aMDRD 80.9 ml/min/1.73m 2 and 3 pts with aMDRD&lt;60. The incidence of de novo Pu during f/u was 36.4% (Table). All pts with Pu at inclusion improved, except one. Among pts with de novo Pu, 58.3% afterwards improved/normalized. No Grade 3/4 Pu has been reported (at inclusion or during f/u) and no Hu. 17.1% developed HTN. In addition, a mean renal function decrease of -2.7 ml/min/1.73m 2 /year was observed and 4 pts had aMDRD&lt;60 at the end of f/u. 36.4% had grade 1 SCr increase (median increase of 15.9%) No thrombotic micro-angiopathy (TMA) has been reported. Conclusions: The results of the MARS subgroup of OC pts shows that 1) TMA remains rare, 2) Pu develops in 36.4% of the pts, however with no Grade 3/4, 3) less than 20% developed HTN, and 4) renal function was not especially impaired. Furthermore, in case of a renovascular effect, investigators followed the recommendations from the French Society of Nephrology (Halimi JM et Al. Nephrol Ther 2008) and no treatment withdrawal for unmanageable renovascular toxicity occurred. [Table: see text]
Absorption, Biotransformation, and Storage of Halothane
Authors: Duncan A. Holaday
Journal: Environmental Health Perspectives (1977)

Current knowledge of the quantitative aspects of biotransformation of halothane and the fate of its metabolites are reviewed. Absorbed quantities of the inhalation anesthetic average 12.7 and 18 g during 1 and 2 hr, respectively, of anesthesia. Reported fractions of halothane recovered as urinary metabolites range from 10 to 25%. An analysis of reports of bromide ion accumulation in plasma during and following anesthesia suggests that metabolism of halothane continues for 20–40 hr after exposure and that 22–24% of absorbed halothane is metabolized following 8 hr of anesthesia. Half-times for excretion of trifluoroacetic acid (TFA), a principal urinary metabolite of halothane, tend to confirm that biotransformation proceeds for 2 to 3 days following exposure. Other urinary metabolites which occur in small amounts include a dehydrofluorinated metabolite of halothane conjugated with L-cysteine and N-trifluoroacetyl-n-ethanolamine, both of which are evidence of the occurrence of reactive intermediates during the metabolism of halothane. Support for free radical formation has come from in vivo and in vitro demonstrations of stimulation of lipoperoxidation of polyenoic fatty acids by halothane. Irreversible binding of halothane metabolites to microsomal proteins and phospholipids has been shown to depend on the microsomal P-450 cytochrome system. Irreversible binding is increased by microsomal enzyme induction and by anaerobic conditions. Hypoxia increases irreversible binding to phospholipids, augments the release of inorganic fluoride and is followed by centrilobular hepatic necrosis. It is concluded that one-fourth to one-half of halothane undergoes biotransformation in man. One fraction is excreted as trifluoroacetic acid, chloride and bromide. A second fraction is irreversibly bound to hepatic proteins and lipids. Under anaerobic conditions fluoride is released, binding to phospholipids is increased, and hepatic necrosis may occur.